Table 1.

Posted results of monotherapy with pembrolizumab, atezolizumab, nivolumab, durvalumab and avelumab in advanced NSCLC

Identifier	Trials	Agent	phase	Indication	Population	Arms	Biomarkers	ORR	mPFS	mOS	mDOR	Adverse effects (grade ≥ 3)
NCT01295827	Keynote 001	Pembrolizumab	I	Second line	Advanced NSCLC	Pembrolizumab	Regardless PD-L1	19.40%	3.7 m	12.0 m	NR	9.50%
							PD-L1 ≥ 50%	45.20%	6.3 m	NR	12.5 m	NA
NCT01905657	Keynote 010	Pembrolizumab	II/III	Second line	Previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells	Pembrolizumab = 2 mg/kg	PD-L1 ≥ 50%	30.00%	5.0 m	14.9 m	NR	13.00%
						Pembrolizumab = 10 mg/kg	PD-L1 ≥ 50%	29.00%	5.2 m	17.3 m	NR	16.00%
						Docetaxel	PD-L1 ≥ 50%	8.00%	4.1 m	8.9 m	8 m	35.00%
NCT02142738	Keynote 024	Pembrolizumab	III	First line	Previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no mutation of EGFR or ALK	Pembrolizumab 200 mg/3 weeks	PD-L1 ≥ 50%	44.80%	10.3 m	NR	NR	26.60%
						Platinum-based chemotherapy		27.80%	6.0 m	14.5 m	6.3 m	53.30%
NCT02220894	Keynote 042	Pembrolizumab	III	First line	Previously untreated advanced non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with ECOG 0 or 1, and a PD-L1 TPS of 1% or greater	Pembrolizumab	PD-L1 ≥ 50%	39.50%	7.1 m	20.0 m	20.2 m	17.80%
							PD-L1 ≥ 20%	33.40%	6.2 m	17.7 m
							PD-L1 ≥ 1%	27.30%	5.4 m	16.7 m
						Platinum-based chemotherapy	PD-L1 ≥ 50%	32.00%	6.4 m	12.1 m	10.8 m	41.90%
							PD-L1 ≥ 20%	28.90%	6.6 m	13.0 m	8.3 m
							PD-L1 ≥ 1%	26.50%	6.5 m	12.1 m	8.3 m
NCT02008227	OAK	Atezolizumab	III	Second line	Previously treated NSCLC	Atezolizumab	ITT population	14.00%	2.8 m	13.8 m	16.3 m	15.00%
						Docetaxel		13.00%	4.0 m	9.6 m	6.2 m	43.00%
NCT01642004/NCT01673867	Checkmate 017/057	Nivolumab	III	Second line	Previously treated patients with advanced squamous or nonsquamous non–small-cell lung cancer	Nivolumab	NA	NA	2.56 m	11.1 m	Squamous: 25.2 m	10.00%
											Non-squamous: 17.2 m
						Docetaxel		NA	3.52 m	8.1 m	Squamous: 8.4 m	55.00%
											Non-squamous: 5.6 m
NCT01693562	Study 1108	Durvalumab	I/II	Second line	Pretreated NSCLC EGFR/ALK wild type	Durvalumab from 0.1 to 10 mg/kg q2w or 15 mg/kg q3w	PD-L1 ≥ 25%	25.30%	2.8 m	15.4 m	NR	10.00%
							PD-L1<25%	6.10%	1.5 m	7.6 m
				First line	Treatmentnaïve advanced NSCLC EGFR/ALK wild type	Durvalumab 10 mg/kg q2w	PD-L1 ≥ 25%	28.60%	4.0 m	21 m	NR	9.00%
							PD-L1<25%	11.00%	NA	NA
NCT02220894	ATLANTIC	Durvalumab	II	Third line	Heavily pretreated advanced NSCLC EGFR/ALK positive	Durvalumab	PD-L1 ≥ 25%	14.10%	1.9 m	13.3 m	7.4 m	5.40%
							PD-L1<25%	3.60%	1.9 m	9.9 m	NR
					Heavily pretreated advanced NSCLC EGFR/ALK wild type or unknown	Durvalumab	PD-L1 ≥ 90%	30.90%	2.4 m	NR	NR	17.60%
							PD-L1 ≥ 25%	7.50%	3.3 m	10.9 m		8.20%
							PD-L1<25%	3.30%	1.9 m	9.3 m
NCT02766335	Lung-Map	Durvalumab	II	Second line	Pretreated NSCLC EGFR/ALK wild type	Durvalumab	PD-L1 ≥ 25%	14.30%	NA	10.7 m	NR	34.00%
							PD-L1<25%	6.90%	NA	11.6 m
						Docetaxel	NA	6.70%	NA	7.7 m	NR	NA
NCT02125461	PACIFIC	Durvalumab	III	Second line	Unresectable stage III NSCLC after chemoradiation Regardless of PD-L1 status	Durvalumab	NA	28.40%	16.8 m	23.2 m	NR	29.90%
						Placebo		16.00%	5.6 m	14.6 m		26.10%
NCT02395172	JAVELIN Lung 200	Avelumab	III	Second line	Platinum-treated patients with advanced NSCLC	Avelumab	PD-L1 ≥ 1%	19.00%	3.4 m	11.4 m	NR	10.00%

Patients can obtain survival and life quality benefits from monotherapy with tolerable adverse reactions

ORR objective response rate, mPFS median Progression Free Survival, mOS median Overall survival, mDOR median Duration of Response, NR not reached, NA nona, ITT intend to treat